Perspective Therapeutics (CATX) Stock News

Perspective Therapeutics (NYSE: CATX) presented two key studies at SNMMI 2025 Annual Meeting in New Orleans. The first presentation focused on dosimetry findings for [212Pb]VMT-α-NET in treating neuroendocrine tumors, demonstrating feasibility and well-tolerated safety profile in Phase 1/2a trials. The study suggests this dosimetric approach could be valuable for developing 212Pb-based therapies. The second presentation introduced [68Ga]PSV377, a novel PET imaging agent for FAP-α expressing tumors, showing promising results in preclinical studies and first-in-human imaging, with superior tumor uptake compared to 18F-FDG in metastatic colorectal cancer patients.

Perspective Therapeutics (CATX) has advanced its Phase 1/2a clinical trial for [212Pb]VMT-α-NET by opening Cohort 3 after FDA alignment. The trial targets patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who haven't received prior radiopharmaceutical therapies. Cohort 3 will administer higher doses (6 mCi) - a 20% increase from Cohort 2. Patients weighing over 60kg will receive four fixed doses every eight weeks, while those under 60kg will receive 100μCi/kg. The company will evaluate dose-limiting toxicities in up to eight patients within 42 days of first treatment to determine maximum tolerated or feasible dose. Initial results from Cohort 2 showed promising anti-tumor activity with primarily low-grade adverse events. The company plans to present additional clinical updates, including safety follow-up and anti-tumor activities, at scientific conferences in the second half of 2025.

Perspective Therapeutics (CATX) presented updated interim data from its Phase 1/2a trial of [212Pb]VMT-α-NET for neuroendocrine tumors at ASCO 2025. The trial showed promising results with 42 patients treated across two cohorts (2.5 mCi and 5.0 mCi). Key findings include: favorable safety profile with no dose-limiting toxicities or treatment discontinuations, 4 out of 7 patients in Cohort 2 achieving objective responses (3 confirmed), and 7 out of 9 patients remaining progression-free after one year. The drug demonstrated durable anti-tumor activity at Cohort 2's dose level, with one patient maintaining response for over 10 months. The company plans to continue dose-finding studies pending FDA consultation and will present additional safety and efficacy data later in 2025.

Perspective Therapeutics (NYSE: CATX) reported key developments for Q1 2025 and provided updates on their clinical pipeline. The company is advancing three clinical-stage radiopharmaceutical therapies: 1. VMT-α-NET: 40 patients enrolled through April 2025 in Phase 1/2a trial for neuroendocrine tumors, with data accepted for ASCO presentation. 2. VMT01: First patients treated with new monotherapy dose and in combination with nivolumab for melanoma treatment. 3. PSV359: Achieved first-in-human dosing for FAP-α targeting therapy for solid tumors. The company is expanding U.S. manufacturing capabilities with two operational facilities and three additional sites under development. Financial position remains strong with $212M in cash and equivalents as of March 31, 2025, expected to fund operations into late 2026. Recent patent allowances strengthen their intellectual property portfolio through 2041-2044.

Perspective Therapeutics (NYSE: CATX), a radiopharmaceutical company focused on advanced cancer treatments, announced its participation in two major healthcare investor conferences in May 2025. The company's senior leadership will be available for one-on-one meetings with investors at both events.

The first appearance will be at the Bank of America Global Healthcare Conference in Las Vegas on May 13, featuring a 15-minute fireside chat at 11:35 a.m. PT. The second presentation will be at the 2025 RBC Capital Markets Global Healthcare Conference in New York on May 20, with a 25-minute fireside chat scheduled for 3:05 p.m. ET.

Perspective Therapeutics (NYSE: CATX) has reached a significant milestone in cancer treatment by dosing the first patient with [212Pb]PSV359 in a Phase 1/2a trial. The study focuses on patients with solid tumors expressing fibroblast activation protein alpha (FAP-α).

The trial aims to evaluate both safety and preliminary anti-tumor activity of this radiopharmaceutical treatment. Patient selection is conducted through SPECT imaging using [203Pb]PSV359. The therapy targets FAP-α, which is present on certain tumors and stromal cells within the tumor microenvironment.

Key developments include:

• Testing [212Pb]PSV359 as both monotherapy and potential combination treatment
• Optimized design for tumor uptake and retention
• Enhanced binding affinity to FAP-α
• Rapid clearance from healthy tissues

This advancement represents Perspective's commitment to developing innovative radiopharmaceutical treatments for various cancers throughout the body.

Perspective Therapeutics (NYSE AMERICAN: CATX) has announced the acceptance of two presentations featuring their radiopharmaceutical programs at the 2025 ASCO Annual Meeting in Chicago (May 30-June 3, 2025).

The presentations will showcase data from two key programs:

• An oral presentation by Thorvardur Halfdanarson on [212Pb]VMT-α-NET therapy for neuroendocrine tumors (NETs), featuring one-year follow-up data on dose-limiting toxicity and preliminary expansion results
• A poster presentation by Zachary Morris discussing interim safety and efficacy data of [212Pb]VMT01 in melanoma treatment

ASCO will release additional abstract details on May 22, 2025, at 5:00 PM EDT.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focused on developing advanced cancer treatments, has scheduled the release of its first quarter 2025 financial results for Monday, May 12, 2025, after market close. The company will also provide a business update at that time. The financial report and business highlights will be accessible through the newsroom section of Perspective's website.

Perspective Therapeutics (NYSE: CATX) has announced the dosing of the first patient in a new cohort of their Phase 1/2a trial evaluating [212Pb]VMT01, a targeted alpha-particle therapy for melanoma patients with positive MC1R imaging scans. The new cohort receives a 1.5 mCi monotherapy dose.

The trial expansion follows encouraging initial monotherapy results presented at the Society for Melanoma Research Congress in October 2024. Notably, this cohort includes patients with brain metastases, supported by previous imaging data showing tracer uptake in brain lesions. A parallel cohort combining [212Pb]VMT01 with nivolumab began in March 2025.